In 2024, we returned $9.5 billion to shareholders via our quarterly dividend, invested $10.8 billion in internal R&D, and as expected, completed business development activity was minimal. Our commitment to de-levering our capital structure to a gross leverage target of 3.25 times by the end of ...
which affected our stock price performance. Despite however this challenging year, there were a few great things that happened in 2023 that may have gotten lost amid the mixed expectations. First, in 2023, Pfizer impacted the lives of more than 620 million ...
Our respiratory vaccines, Abrysvo and Prevnar 20, also are key products in our commercial portfolio. We have achieved a market leadership position for the season in shipped doses for Abrysvo with an approximately 13 percentage points increase in market share, and remain confident in our ability ...
1.45 Market Cap: $ 130.76B Enterprise V: $ 174.07B Volume: 31.41M Avg Vol (2M): 58.69M Warning! GuruFocus detected 4 Severe warning signs with PFE.Try a 7-Day Free Trialto check it out. Trade In: What is a stock summary page? Clickherefor an overview. ...
Stock Market Holidays & Hours After Hours Trading Portfolio Management Cryptocurrency Dividend Investing Portfolio Strategy Fixed Income Retirement IPO's Podcasts Video Hub Editors' Picks Stock Analysis Stock Ideas Long Ideas Stock Upgrades & Downgrades Editors' Picks Quick Picks & Lists Emerging ...
First-quarter 2024 Cost of Sales(2) as a percentage of revenues decreased by 3.7 percentage points compared with the prior-year quarter, driven primarily by favorable changes in sales mix, including lower sales of Comirnaty(1), which resulted in a lower related charge for the 50% gross prof...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2023. The company reaffirms its 2023 revenue guidance(4)range of $58.0 to $61.0 billion and its outlook for Adjusted(3)diluted EPS of $1.45 to $1.65 provided on October 13, 2023. ...
(where the reported amount of US$7.85 billion missed estimates of US$7.89 billion), PayPal raised its 2024 profit outlook from its prior forecast of ‘low to mid-teens’ to ‘high-teens’ percentage range, citing solid consumer spending and partnerships with key commerce players such as Fiserv...
Pfizer expects its fiscal 2016 adjusted cost of sales to be between21.5% to 22%, which puts its gross margin around 78%,14percentage points higher than Merck’s through the first nine months of fiscal 2016. Although Merck’s have been improving lately, Pfizer’s are still much healthier. ...
In addition, Pfizer anticipates achieving Income Before Tax margins (expenses as a percentage of revenue plus other income and deductions) in the mid-30s% range and operating cash flow of $11 - $12 billion. Pfizer also expects that followi...